Results 141 to 150 of about 21,255 (259)

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Environmental impacts from European food consumption can be reduced with carbon pricing or a value-added tax reform. [PDF]

Nat Food
Plinke C, Sureth M, Kalkuhl M.
europepmc   +1 more source

Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024. [PDF]

China CDC Wkly
Ren J, Wang N, Zhu H, Nie W, Sun F, Xiong Y, Fu L, Luo H, Cheng S, Zhao Y, Huang F.   +10 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Land Finance and fiscal rules: An estimated DSGE model for Hong Kong. [PDF]

PLoS One
Zhang W, Liu Z.
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Accuracy of Budget Impact Projections in Bulgarian Health Technology Assessment: A Five-Year Validation Study (2020-2025). [PDF]

Healthcare (Basel)
Kostadinov K, Raycheva R, Zdravkova-Aneva I, Shopova M, Ovchinnikov E, Petkov P.   +5 more
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Physician agency in China: evidence from physicians' responses to financial pressure during the COVID-19 pandemic. [PDF]

Health Econ Rev
Zhang Q.
europepmc   +1 more source

THEORIZATION OF THE BUDGETING FOR MILITARY EXPENDITURES

Scientific Notes of Ostroh Academy National University, "Economics" Series, 2019
openaire   +2 more sources